 |
|
|
| |
BIC/FTC/TAF as HIV PEP was well-tolerated with high adherence and no seroconversions
|
| |
| |
Darrell H. S. Tan1,2,3, Reva Persaud1, Attia Qamar4, Isaac Bogoch2,5, Arlene Chan6, Allison Chris7, Karla Fisher5, Richard T. Lester8, John Maxwell9, James Murray10, Hong Qian11, Hubert Wong1
1. MAP Centre for Urban Health Solutions, St. Michael’s Hospital, Toronto, Canada; 2. Division of Infectious Diseases, St. Michael’s Hospital, Toronto, Canada; 3. Department of Medicine, University of Toronto, Toronto, Canada;
4. Scarborough Health Network, Toronto, Canada; 5. Division of Infectious Diseases, Toronto General Hospital; 6. Women’s College Hospital, Toronto, Canada; 7. Toronto Public Health, Toronto, Canada; 8. University of British Columbia, Vancouver, Canada;
9. AIDS Committee of Toronto (ACT), Toronto, Canada; 10. AIDS Bureau, Ontario Ministry of Health and Long-Term Care, Toronto, Canada; 11. CIHR Canadian HIV Trials Network, Vancouver, Canada
|
| |
|
|
|
|
|
